Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582798 | 0.87 | MCHR1 (1.00) | MCHR1HTR2C | |
| SCHEMBL5582658 | 0.86 | MCHR1 (1.00) | MCHR1HTR2CNPC1RAB9A | |
| SCHEMBL5582498 | 0.86 | MCHR1 (0.98) | MCHR1HTR2C | |
| SCHEMBL5582522 | 0.86 | MCHR1 (1.00) | MCHR1HTR2CNPC1RAB9A | |
| SCHEMBL5582935 | 0.86 | MCHR1 (1.00) | MCHR1HTR2C | |
| SCHEMBL5582620 | 0.85 | MCHR1 (0.81) | MCHR1HTR2C | |
| SCHEMBL5582708 | 0.85 | MCHR1 (1.00) | MCHR1HTR2C | |
| SCHEMBL5582560 | 0.85 | MCHR1 (0.98) | MCHR1HTR2CNPC1RAB9A | |
| SCHEMBL5582932 | 0.84 | MCHR1 (1.00) | MCHR1HTR2CKMT2A | |
| SCHEMBL5582582 | 0.83 | MCHR1 (0.79) | MCHR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885HTR2C 195/4885NPC1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.